
Company valuation, historical trends, and peer comparisons.
According to NewAmsterdam Pharma Company N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.90B. This represents a change of -43.81% compared to the average of 3.39B of the last 4 quarters.
The mean historical Enterprise Value of NewAmsterdam Pharma Company N.V. over the last ten years is 965.57M. The current 1.90B Enterprise Value has changed 97.06% with respect to the historical average. Over the past ten years (40 quarters), NAMS's Enterprise Value was at its highest in in the June 2026 quarter at 3.76B. The Enterprise Value was at its lowest in in the September 2022 quarter at -290624530.00.
Average
965.57M
Median
382.17M
Minimum
-260870038.50
Maximum
3.52B
Discovering the peaks and valleys of NewAmsterdam Pharma Company N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 186.44%
Maximum Annual Enterprise Value = 3.52B
Minimum Annual Increase = -331.11%
Minimum Annual Enterprise Value = -260870038.50
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 3.52B | 113.06% |
| 2024 | 1.65B | 186.44% |
| 2023 | 577.34M | -321.31% |
| 2022 | -260870038.50 | -331.11% |
| 2021 | 112.88M | -39.64% |
The current Enterprise Value of NewAmsterdam Pharma Company N.V. (NAMS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.92B
5-year avg
1.12B
10-year avg
965.57M
NewAmsterdam Pharma Company N.V.’s Enterprise Value is greater than BioAge Labs Inc. (141.21M), greater than Alterity Therapeutics Limited (21.31M), less than Amylyx Pharmaceuticals, Inc. (3.47B), less than Madrigal Pharmaceuticals, Inc. (10.00B), greater than MetaVia Inc. (-4551279.00), less than Viking Therapeutics, Inc. (3.01B), greater than Acumen Pharmaceuticals, Inc. (-7542241.00), greater than CervoMed Inc. (2.64M), less than Denali Therapeutics Inc. (2.82B), less than Septerna Inc (1.92B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 141.21M | $212.34M | |
| 21.31M | $37.36M | |
| 3.47B | $3.51B | |
| 10.00B | $9.94B | |
| -4551279.00 | $7.91M | |
| 3.01B | $3.43B | |
| -7542241.00 | $19.26M | |
| 2.64M | $25.10M | |
| 2.82B | $3.00B | |
| 1.92B | $1.99B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NewAmsterdam Pharma Company N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NewAmsterdam Pharma Company N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is NewAmsterdam Pharma Company N.V.'s Enterprise Value?
What is the highest Enterprise Value for NewAmsterdam Pharma Company N.V. (NAMS)?
What is the 3-year average Enterprise Value for NewAmsterdam Pharma Company N.V. (NAMS)?
What is the 5-year average Enterprise Value for NewAmsterdam Pharma Company N.V. (NAMS)?
How does the current Enterprise Value for NewAmsterdam Pharma Company N.V. (NAMS) compare to its historical average?